Twenty Famous Names in Consumer Diagnostics, One Question: Is There a Clinician?

2026 ·11 minute read · By Sumesh Peringeth

In short

Twenty famous consumer-diagnostics names were ruled against one question: does the individual receive both a result and a structured clinical interpretation or defined next step. Eight pass, five fail outright as products, and seven sit on the line. The eight passers almost all arrived at care from somewhere else, and the arrival is dated: Function Health acquired the imaging company Ezra on May 5, 2025; WHOOP launched clinician-reviewed Advanced Labs on September 30, 2025; Levels sells clinician review of health data twice annually inside a $499 tier and not in its $80 tier. Oura and 23andMe never added a clinical layer to the consumer product, and fail. 23andMe itself was bought out of Chapter 11 by the nonprofit TTAM Research Institute on July 14, 2025.

Twenty of the best-known names in consumer health diagnostics were ruled against a single question. Does the person who pays receive a result and a clinical interpretation or a defined next step, or do they receive only the result. Eight pass. Twelve do not.

The pass rate is the least interesting thing on the list. What the twenty actually show is that almost none of the passers started as care. Function Health bought an imaging company. WHOOP bolted clinician-reviewed labs onto a fitness strap. Levels put clinician review behind a $499 tier and left it out of the $80 one. Oura and 23andMe never did any of it, and fail. A consumer product category is converting itself into healthcare one clinician at a time, and for most of these companies the conversion has a date on it.

This piece records the ruling and the pattern. It does not rank these companies, does not recommend any of them, and is not medical advice.

What is the question, and why is it the only one asked here?

Two tests, both published in the Atlas scope policy, and both narrow on purpose.¹

A result without interpretation is a product, not care. An organization that returns a measurement, whether a scan, a blood panel or a genomic report, qualifies only if the individual also receives a structured clinical interpretation or a defined next step. A kit that returns a number does not qualify. A service that returns a number and a clinician’s read does.¹

Follow the customer. An organization qualifies only where the individual chooses and receives the service. Where the buyer is a hospital, payer, employer or pharmaceutical company and the individual never selects the provider, it is business-to-business and is not recorded, whatever its clinical subject matter.¹

Neither test is a judgment about whether a product is good, useful or well built. A ring that measures sleep well is a good ring. It is not a healthcare provider, and a record that counts it as one has stopped meaning anything. The Atlas has argued the same point from the other direction before, in half of what calls itself a longevity clinic is not one.

Every verdict below was reasoned against the operator’s own live site or a primary release, and where a site could not be read, that failure is recorded rather than substituted with directory evidence.²

Which of the twenty pass?

Eight, and the shape they share is a clinician attached to a measurement.

Prenuvo pairs whole-body MRI and blood biomarkers with personalized results reviews, and its own site describes a Prenuvo Medical Group of more than two hundred healthcare professionals including radiologists, MRI technologists, preventative health physicians and nurse practitioners. From $1,199.² See Prenuvo.

Neko Health runs an hour-long sensor scan with a clinician consultation in the same visit. It is the cleanest passing shape in the category, because the interpretation is not an add-on, a tier or a written note; it is the appointment.² The Atlas records Neko as two Stockholm premises rather than one company row, so there is no single entity link: see Neko Health (Mood) and Neko Health (Ostermalmstorg).

Ezra passes on the merits and is no longer an independent operator, which is the subject of the next section. See Ezra.

Function Health sells membership lab testing with clinician review, and now imaging as well.² See Function Health.

Superpower states on its own site that it delivers more than a hundred biomarkers, a clinician-grade action plan after every test, and on-demand care team support, at $199 a year with pricing that varies in New York and New Jersey.²

Hundred Health states more than a hundred advanced lab tests and a hundred-day personalized protocol described as clinician-reviewed, at $199 and $499 a year.²

Q Bio is the only name in the twenty that is a new pass and not already known to the Atlas. Its own site describes a Q Exam combining whole-body MRI, biomarkers, genetics, wearable data and medical history, with a board-certified physician interpreting the full record in a forty-five-minute data review and a radiologist reading the imaging, from a clinic in Redwood City, California.²

Human Longevity Inc / Health Nucleus combines genome sequencing, whole-body imaging and biomarkers, with an executive health tier at $8,000 a year that includes dedicated clinician review.² See Human Longevity Inc / Health Nucleus.

Three of those eight, Superpower, Hundred Health and Q Bio, are open candidates rather than recorded rows, so they carry no entity link here. Passing a scope test is not the same as being verified, dated and published, and this record does not blur the two.

Which fail outright, and on which test?

Five, and all five fail on interpretation rather than on the customer.

Viome sells a kit, an algorithmic report across what it describes as more than four hundred biological pathways, and a supplement subscription. No clinician interpretation is offered, and the site states that results are not a substitute for professional medical advice.²

Zoe states outright that its products are not intended to diagnose, prevent, monitor or treat any medical condition. It is a nutrition program with a test kit and supplements.²

Oura is a ring and an app, with no clinical tier, no clinician interpretation and no care pathway found on its own site.²

23andMe sells a $119 saliva kit with no clinician review or genetic counseling in the consumer product, and its own site says results should be confirmed in a clinical setting before any medical action is taken.²

Nucleus Genomics sells consumer genomics with an embryo product offering to preview a prospective child’s predicted eye color, height and intelligence. A named genetic reproductive counselor appears on the site, but counseling is not established as included. It fails the interpretation test as read and the healthy-years intent test as well.²

The honest way to read this column is that these are five successful consumer products that were never trying to be care. Oura sells a good ring. The finding is about which map they belong on.

Seven sit on the line, and the line is where the category is moving

Seven cases could not be resolved on their own published material, and they are more informative than either clean column.

InsideTracker and TruDiagnostic are both already recorded in the Atlas, and on this reading neither one’s own site established that a clinician interprets results for the individual buyer. Those are verification flags against existing rows, not proposals to remove them.² See InsideTracker and TruDiagnostic.

GRAIL, which sells the Galleri multi-cancer test, states that the test is prescription-only and that results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. The interpretation is explicitly delegated to somebody else’s clinician, and the company sells to patients, providers, employers, health systems and insurers alike. GRAIL supplies the assay; the pathway belongs to a third party.²

Everlywell sells mail-in kits from $49 to $949 with virtual visits offered alongside, and its own site did not establish clinician review as standard rather than an upsell.²

LetsGetChecked has a genuine clinical layer, including physician review of results and a nurse call on abnormal results, but its own site headline sells home test kits and enterprise wellness solutions together and it states more than three hundred employers, health plans and providers as customers. That is a follow-the-customer tension rather than an interpretation one.²

Levels is the sharpest illustration of the whole pattern, because its clinician is priced. On its own site as of August 2026, the Build tier is $15 a month or $80 billed annually and includes the app, food logging and AI health insights, with no clinician. Core is $499 billed annually and includes, in the company’s own words, clinician review of health data twice annually. Complete is $1,999 billed annually and adds comprehensive labs, a fifty-minute functional nutritionist session and concierge support.³ The same company sells a product and sells care, and the boundary between them is a price.

WHOOP is the closest thing in the sweep to a controlled experiment on the first test. WHOOP Advanced Labs launched on September 30, 2025 with Quest Diagnostics. The launch release states that clinician-reviewed results provide expert context and personalized recommendations, covers 65 biomarkers, states that tests are reviewed and ordered by a licensed healthcare provider, and prices the subscription at $199 for one test, $349 for two a year and $599 for four.⁴ What the release does not describe is a consultation. The clinician writes context into the app and the member never speaks to one. Whether that clears the interpretation test is exactly the question the test was written to force, and it is not resolved here.

Signos was added to the line by the same logic even though it was not on the starting list. It sells CGM plus an app from $129 a month, and its own terms state that clinical services are provided solely by OpenLoop Health and other independent networks of United States licensed clinicians. The clinician is real and is not the company’s.²

The conversion is real, and most of it is dated

This is the finding. Read the passers and the line cases together and the eight are not a set of healthcare companies that happen to sell diagnostics. They are consumer companies that acquired, hired or priced their way into a clinical layer, mostly recently, and mostly on the record.

Function Health acquired Ezra on May 5, 2025, and stated in the same release that it would cut the full-body MRI from 60 minutes to 22 minutes and from over $1,500 to $499.⁵ An imaging company became the imaging arm of a lab-testing membership in a single transaction. The Atlas carries Function Health and Ezra as separate rows and does not yet record the ownership link between them, which is a gap in the record rather than a question about the fact.

WHOOP added a clinical layer on September 30, 2025. A company whose product was a strap on a wrist now orders blood tests through a national laboratory and has a licensed provider review them.⁴

Levels drew its clinical layer as a price line, and the line was visible on its plan comparison in August 2026: no clinician at $80 a year, clinician review twice annually at $499.³

Oura and 23andMe did not. Both remain, on their own published material, products. 23andMe’s corporate life changed a great deal in the same window, and none of it was clinical: the company filed for Chapter 11 in March 2025, and TTAM Research Institute, a nonprofit public benefit corporation founded and led by Anne Wojcicki, completed the acquisition of its Personal Genome Service and Research Services business lines on July 14, 2025 for $305 million.⁶⁷ That is why 23andme.com now returns a 301 redirect to 23andme.org.⁸ A change of owner is not a change of delivery model, and the verdict here is unmoved by it.

Set against the founders piece the Atlas published on the same category, this is the other half of the same observation. Tech founders keep building body-scanning companies because the imaging has become a component to license rather than a problem to solve. What the twenty names here add is that the clinician has become a component too: something a consumer company can acquire in a transaction, contract from a laboratory partner, or install at a price point, years after the product shipped.

What the pattern does not mean

Three qualifications, each of which cuts against the easy reading.

The first is the comparison that makes the pass rate look high rather than low. The Atlas ran the same famous-names test across femtech and one of ten names passed; seven of the ten were consumer hardware or tracking apps with no clinician in the loop, and two of those seven turned out to be the same corporate group.⁹ Consumer diagnostics passes several times more often than femtech does, and the reason is structural rather than flattering. Diagnostics was built by companies that sell a test, and a test is one clinician away from being care. A period-tracking app is much further from it. That is a fact about how close each category started to the line, not a verdict on either.

The second is that a clinician on a pricing page is not evidence that the underlying screening works. The Atlas has recorded separately that the price of a full-body scan has fallen by roughly two-thirds in about a year while the published evidence for screening asymptomatic people has not moved with it.¹⁰ Adding a clinical read to a scan changes what the organization is. It does not change what the scan is worth.

The third is that seven of the twenty are unresolved and are recorded that way deliberately. A sweep that forces every case into pass or fail produces a cleaner table and a worse record. The line cases are where the category is actually moving, and the useful thing to publish about them is the tension, not a verdict.

The Atlas of the Healthspan Economy is a neutral record of organizations working on healthspan. It does not recommend any provider or any test. See Prenuvo, Ezra, Function Health, Human Longevity Inc / Health Nucleus, InsideTracker, TruDiagnostic and the Healthtech & Diagnostics pillar, and read the methodology.

A note on what this piece does not claim. Nothing here is medical advice, a recommendation or a ranking, and no company is described as better or worse than another. A verdict of pass means an organization is in scope for a record of care delivered to individuals; it does not mean the service is effective, well priced or worth buying, and a verdict of fail says nothing about product quality. The seven line cases are unresolved rather than rejected, and two of them, InsideTracker and TruDiagnostic, are verification flags against rows already published, not proposals to remove them. Superpower, Hundred Health and Q Bio pass the scope test as open candidates and are not recorded rows, so no Atlas record of them is asserted. Prenuvo’s only location outside the United States, Canada, the United Kingdom and Australia is a Dubai site its own page marks as coming soon; no operating Prenuvo presence in the United Arab Emirates, Singapore, Sweden or Switzerland is claimed here. The 23andMe ownership change is recorded as a corporate fact and plays no part in the verdict, which rests on the consumer product. Prices and site wording are as published on each company’s own material on the dates cited and will move.

Healthspan Economy, Atlas scope policy, delivery bar, two tests. “A result without interpretation is a product, not care” and “Follow the customer,” with worked examples qualifying Prenuvo, Neko Health and Function Health, failing ID Formulas, Viome and Oura as products, and failing Lunit, MICIN and Insighta as business-to-business. Read the methodology for how the Atlas applies it. ↩ ↩² ↩³
Healthspan Economy, Healthtech and Diagnostics pillar discovery sweep, August 8, 2026. Internal discovery record, not a published article. Twenty famous names ruled against the delivery bar with each verdict reasoned against the operator’s own live site where the site could be reached; search was run in Japanese, Korean, German, French, Spanish, Portuguese, Swedish, Dutch and Italian as well as English. Company self-descriptions, prices and site wording in this piece are quoted from that record’s own-site reads unless a separate primary source is cited. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸
Levels, official site, plan comparison, read August 9, 2026. Build your system, $15 a month or $80 billed annually, with glucose monitoring, labs and dietitian support listed as paid add-ons and no clinician review included. Core, $499 billed annually, including “Clinician review of health data 2x annually,” two essential lab panels with 28 or more markers and one month of continuous glucose monitoring. Complete, $1,999 billed annually, including the same clinician review line, two comprehensive labs with 100 or more markers, two months of continuous glucose monitoring, a fifty-minute functional nutritionist session and dedicated concierge support. Recorded discrepancy: the company’s own support knowledge base files Core and Complete as legacy plans and lists only the $15 monthly and $80 annual options as current, while the live site sells all three. The own-site plan comparison is the reading taken here, because it is the page a buyer transacts on. https://levels.com ↩ ↩²
“WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health,” September 30, 2025, published in the Quest Diagnostics newsroom. “Clinician-reviewed results provide expert context and personalized recommendations”; 65 biomarkers; tests reviewed and ordered by a licensed healthcare provider; subscription priced at $199 for one test, $349 for two tests per year and $599 for four, with additional tests at discounted rates. The release does not describe a member consultation. https://newsroom.questdiagnostics.com/2025-09-30-WHOOP-Launches-Clinician-Reviewed-Advanced-Labs,-Unlocking-a-Comprehensive-View-of-Human-Health ↩ ↩²
Function Health, “Function Health Acquires Ezra, Introduces $499 Full-Body MRI Scan,” PR Newswire, dateline May 5, 2025. “Full Body MRI scan now takes just 22 minutes instead of 60 minutes, costs $499 instead of over $1,500.” Figures are the acquirer’s own announcement. Re-verified August 9, 2026. https://www.prnewswire.com/news-releases/function-health-acquires-ezra-introduces-499-full-body-mri-scan-302446016.html ↩
“TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets,” GlobeNewswire, July 14, 2025. Completion of the acquisition of the Personal Genome Service and Research Services business lines of 23andMe Holding Co. under section 363 of the US Bankruptcy Code, under an asset purchase agreement dated June 13, 2025, for a total purchase price of $305.0 million in cash. https://www.globenewswire.com/news-release/2025/07/14/3114916/0/en/TTAM-Research-Institute-A-Nonprofit-Public-Benefit-Corporation-Completes-The-Acquisition-of-23andMe-Assets.html ↩
23andMe, “23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation,” June 30, 2025, announcing approval by the US Bankruptcy Court for the Eastern District of Missouri at a purchase price of $305 million, with the transaction then expected to close in the following weeks. TTAM outbid Regeneron Pharmaceuticals, which had agreed to acquire the assets for $256 million. https://www.23andme.org/media-center/press-releases/23andme-receives-court-approval-sale-ttam-research-institute/ ↩
Verified August 9, 2026: https://23andme.com and https://www.23andme.com each return HTTP 301 to https://www.23andme.org/. ↩
Healthspan Economy, femtech and women’s health discovery sweep, August 8, 2026. Internal discovery record, not a published article. Ten famous names ruled against the same delivery bar, one pass; seven of the ten were consumer hardware or tracking apps with no clinician in the loop, and Elvie and Willow were found to be a single corporate group rather than two organizations. ↩
Healthspan Economy, “The scan is getting cheaper than the appointment,” recording the fall in full-body scan pricing against an unchanged evidence base for screening asymptomatic people. /insights/the-scan-is-getting-cheaper-than-the-appointment ↩

Related insights

Why Are Tech Founders Starting Body-Scanning Companies?
Four consumer-technology founders with no medical background have built or announced full-body scanning companies. The scan itself is collapsing in time and price, the newest entrant has no healthcare history at all, and the published evidence on screening asymptomatic people has not changed. The founder who built the clinical stack instead of the funnel closed after raising $13.25 million.
The scan is getting cheaper than the appointment
Full-body scanning is dropping fast in time and price, and an AI image company has announced a 60-second scanner it has not built. A cheaper scan finds more, which is not automatically good.
Vietnam, the market with no map
Vietnam has a forming preventive-health market that English-only searching renders invisible. Six organizations are now on record, found by searching in Vietnamese as well as English.
Half of what calls itself a longevity clinic is not one
When a longevity-branded batch is checked against what each operator actually delivers, a large share turns out to be wellness or aesthetics, not longevity medicine. The problem is scope, not honesty, and one regulator now draws the same line.

Questions

Frequently asked questions

What test separates a consumer diagnostic product from healthcare?

The Atlas applies two delivery-bar tests. First, a result without interpretation is a product, not care: an organization that returns a scan, a panel or a genomic report qualifies only if the individual also receives a structured clinical interpretation or a defined next step. Second, follow the customer: where the buyer is a hospital, payer, employer or pharmaceutical company and the individual never selects the provider, the organization is business-to-business and is not recorded, whatever its clinical subject matter. Both tests are published in the Atlas scope policy.

Which famous consumer-diagnostics names clear the bar?

Eight of the twenty ruled in this sweep: Prenuvo, Neko Health, Ezra, Function Health, Superpower, Hundred Health, Q Bio and Human Longevity Inc / Health Nucleus. Each pairs a measurement with a clinician's read or a defined next step, and in each case the individual is the buyer. Prenuvo, Neko Health, Ezra, Function Health and Human Longevity are recorded in the Atlas. Superpower, Hundred Health and Q Bio are open candidates and are not recorded rows.

Which names fail outright?

Five, all on the interpretation test rather than the customer test: Viome, Zoe, Oura, 23andMe and Nucleus Genomics. Each sells a measurement, an algorithmic report or a device to an individual with no clinician reading the result for that individual. Zoe's own site states its products are not intended to diagnose, prevent, monitor or treat any medical condition. 23andMe's own site directs that results should be confirmed in a clinical setting before any medical action is taken.

Did Function Health acquire Ezra, and when?

Yes. Function Health announced the acquisition of Ezra on May 5, 2025, and stated in the same release that it would cut the full-body MRI from 60 minutes to 22 minutes and from over $1,500 to $499. The Atlas records Function Health and Ezra as separate rows and the ownership link between them is not yet recorded.

Does WHOOP offer clinician-reviewed blood testing?

Yes, since September 30, 2025, when WHOOP launched Advanced Labs with Quest Diagnostics. The launch release states that clinician-reviewed results provide expert context and personalized recommendations, covers 65 biomarkers, and prices the subscription at $199 for one test, $349 for two tests a year and $599 for four. The release describes a clinician review written into the app and does not describe a consultation, which is why the case sits on the line rather than clearly above it.

Who owns 23andMe now?

TTAM Research Institute, a nonprofit public benefit corporation founded and led by Anne Wojcicki, completed the acquisition of 23andMe's Personal Genome Service and Research Services business lines on July 14, 2025 for $305 million, under section 363 of the US Bankruptcy Code following a Chapter 11 filing in March 2025. This is why 23andme.com now returns a 301 redirect to 23andme.org. The change of owner does not change the verdict here, which is about the consumer product and not about the company's balance sheet.